Eli Lilly and Company
ACYLATED INSULIN COMPOUND

Last updated:

Abstract:

The presently described compounds relate to the treatment of diabetes and/or hyperglycemia. More particularly, the described compounds relate to acylated insulin compounds that lower blood glucose, pharmaceutical compositions containing such compounds, therapeutic uses of such compounds, and an intermediate compound used to make the acylated insulin compounds.

Status:
Application
Type:

Utility

Filling date:

1 Aug 2019

Issue date:

14 Nov 2019